Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting

Abstract

Introduction: Knowledge on the efficacy and safety of adalimumab in psoriasis patients switching from etanercept is scarce, especially on the influence that causes of etanercept discontinuation may have on adalimumab response.

Objectives: To evaluate the response, adverse effects and factors that may influence the efficacy and safety of adalimumab in psoriasis patients who failed on etanercept therapy in a real-world setting.

Methods: Data from all moderate to severe plaque psoriasis patients who switched from etanercept to adalimumab were extracted from a registry of biological therapies of our department. Primary endpoint was the percentage of patients achieving PASI 50 at weeks 12, 24, and 52. Secondary endpoints were the percentages of patients achieving PASI 75 and PASI 90, patients who maintained PASI values <5 and <3, and the safety of adalimumab.

Results: Of 35 patients who fulfilled the study criteria, 82.9% achieved PASI 50 at week 12, 74.3% at week 24, and 74.3% at week 52 on adalimumab treatment. Eleven of 16 primary and 11 of 17 secondary nonresponders to etanercept responded to adalimumab. There were no treatment discontinuations due to side effects.

Conclusions: Previous etanercept failure seems not influence the success and safety of adalimumab treatment in moderate to severe plaque psoriasis.

• Adalimumab
• anti-tumor necrosis factor-alpha
• biologic therapy
• etanercept
• psoriasis

Declaration of interest

Eduardo Fonseca, Sabela Paradela, and Rosa M. Fernández-Torres have participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis and in continuing medical education events supported by unrestricted educational grants from Abbvie, Celgene, Janssen-Cilag, Leo, MSD, and Pfizer.